BackUSFDA bans import of drugs from Wockhardt’s Ankleshwar plant
US health regulator has banned import of drugs produced at Wockhardt's Ankleshwar plant for non-compliance of manufacturing norms
Premium
New Delhi: In yet another blow to drug maker Wockhardt, US Food and Drug Administration (USFDA) has banned import of products manufactured at its Ankleshwar plant for non compliance of manufacturing norms.
The company’s Ankleshwar plant manufactures bulk drugs, the USFDA said in a notice on its website. The import alert has been issued under ‘Import Alert 66-40’, which authorises the health regulator “detention without physical examination of drugs from firms which have not met drug GMPs".
Already the company’s two plants at Chikalthana and Waluj have been banned from exporting drugs to the US by the US health regulator. In November 2013, the USFDA had imposed restrictions on import of medicines produced at the company’s Chikalthana plant at Aurangabad in Maharashtra.
Earlier in May, the USFDA had also issued an import alert on the company’s Waluj facility which makes injectables and solid dosages. Wockhardt shares ended at ₹ 1,015.60 on BSE, up 0.49% from the previous close.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
